Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology
Would you consider using tamoxifen in ER-negative DCIS?
Not to decrease recurrence risk, but for chemoprevention of new ER-positive DCIS or invasive disease based on the Gail Model. If so, is there data to quantify the benefit in this situation?
Answer from: Medical Oncologist at Academic Institution
In the placebo-controlled NSABP-B24 trial, tamoxifen reduced the risk of ipsilateral and contralateral second events by 30% and 52%, respectively, when added to BCS and radiation. In a reanalysis of a subset of participants with estrogen receptor expression information, this benefit was most apparen...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
no
Answer from: Medical Oncologist at Academic Institution
In the randomized controlled trials of adjuvant tamoxifen for DCIS, only women with hormone receptor-positive tumors benefited. Also there is a strong correlation between hormone receptor status of the primary breast cancer and contralateral second breast primaries. Therefore, women with a history o...